Pipeline

Psivant Therapeutics has a differentiated pipeline of targets with high biological and disease validation that have historically provided challenges for the design of therapeutics.

Target
Area of Focus
Exploratory
Discovery
Pre-Clinical

Tumor Necrosis Factor Superfamily

TL1A

Focus: Inflammation and Immunology

Status: Discovery

CD40L

Focus: Inflammation and Immunology

Status: Discovery

RANKL

Focus: Inflammation and Immunology

Status: Discovery

BAFF

Focus: Inflammation and Immunology

Status: Exploratory

OX40L

Focus: Inflammation and Immunology

Status: Exploratory

Dual Kinase Inhibitors

WEE1/MYT1

Focus: Oncology

Status: Discovery

IRAK1/IRAK4

Focus: Inflammation and Immunology

Status: Discovery